2017 Connecticut Cancer Partnership Annual Meeting Presenters & Presentation Slides

  Event Held on Tuesday, Dec. 5, 2017 Screening Guidelines and Shared Decision-Making Challenges, Controversy, Disparities Event Agenda and Acknowledgements Our speakers included: Beth Jones, PhD, MPH, Director, Smilow Screening & Prevention Program, Assistant Director for Diversity and Health Equity, Yale Cancer Center, Research Scientist and Lecturer, Yale School of Public Health .  Dr. Jones is a cancer epidemiologist whose work and teaching focus is on health disparities. Her current research is focused on racial/ethnic differences in cancer screening and cancer outcomes. Cancer Screening: Setting the Stage – Challenges, Controversy and Health Disparities Polly Sather, MSN, APRN, Advanced Practice Registered Nurse (APRN)…

New Emerging Issues Brief

Refusing Cancer Medications to Avoid Delirium and Maintain Autonomy By Kimberly Petrovic, PhD MSN MA RN, Assistant Professor of Nursing, SCSU Thomas O. Blank, Ph.D., Professor Emeritus, Human Development and Family Studies, UConn    Shared decision-making within the patient-provider relationship is considered a cornerstone of the contemporary treatment of cancer here in Connecticut as well as nationally. It will be the focus of the 2017 Annual Meeting of the Connecticut Cancer Partnership. The relationship between patient and provider is critical and needs to develop and grow without diminishing the ultimate goals of cancer treatment: cure (whenever possible) and comfort (as…

The Role of Genomics in Breast Cancer

Join The Jackson Laboratory for Genomic Medicine (JAX) for three upcoming educational events on the role of genomics in breast cancer. Through a generous grant from the Connecticut Breast Health Initiative Inc., these unique events will incorporate perspectives from breast cancer survivors, clinicians, and researchers to provide insight into current and future uses of genomics in breast cancer detection, diagnosis, treatment, and ongoing management.   Beyond Genetics: genomics in breast cancer diagnosis, treatment and research Register here for the April 18, 2017  event – Early detection and diagnosis Register here for the May 2, 2017 event – Treatment and Precision…

Triple Negative Breast Cancer Research from Yale

Researchers at Yale Cancer Center have identified a new subtype of triple negative breast cancer that shows significantly improved response to chemotherapy. Patients with the newly defined subtype — BRCA-deficient triple negative breast cancer — had significantly higher survival rates with chemotherapy. The study was published on Dec. 13 in PLOS Medicine. Triple negative breast cancer (TNBC) disproportionately affects young women of all races and women of African ancestry, contributing to health disparities. In an era when personalized cancer therapy has improved survival rates, patients with TNBC remain at considerably higher risk of relapse and death than patients with other…